Cambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity at Its Charles City, Iowa Facility
August 08 2017 - 8:00AM
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small
molecule innovator and generic Active Pharmaceutical Ingredients
(APIs), today announced that it is to invest $24 million in a new
facility to manufacture highly potent APIs (HPAPIs) at its Charles
City, Iowa plant.
The 4,500 sq. ft. production area will operate
to an occupational exposure limit (OEL) down to 0.1µg/m3 and have a
total reactor capacity of 2,200 gallons, which will be made up from
a range of 200, 500 and 1,000 gallon glass and Hastelloy vessels to
manufacture batches from 50 to 300kg.
The project will also reconfigure the existing
small scale manufacturing area providing a single high containment
building to support early stage development and manufacturing,
providing flexibility across a broad range of scale. Construction
and installation of all new equipment is expected to be completed
by Q1 2019.
“This expansion is in line with Cambrex’s
commitment to ongoing investment in small molecule manufacturing,
as well as responding to the rising number of APIs that require
specialized handling due to potency and toxicity,” commented Shawn
Cavanagh, COO of Cambrex. He added, “Cambrex has built a strong
reputation in the clinical-scale supply of potent, and extremely
potent molecules, and the flexibility that this facility will give
allows us to effectively handle projects throughout their
development and commercial life-cycle.”
This latest expansion is part of an ongoing
strategic campaign to invest in small molecule API development and
manufacturing across Cambrex’s global network of facilities, and
follows the opening of a $50 million, 7,500 sq. ft. multi-purpose
manufacturing facility at Charles City in 2016, which added a total
of 70m3 of manufacturing capacity to the site.
Cambrex’s Charles City, Iowa facility is located
on a 45-acre site and manufactures a wide range of APIs and
pharmaceutical intermediates, including highly potent molecules and
controlled substances. The facility is one of a limited number
authorized by the US DEA to import narcotic raw materials at
commercial scale.
About
CambrexCambrex Corporation is an innovative life
sciences company that provides products, services and technologies
to accelerate the development and commercialization of small
molecule therapeutics. The Company offers Active
Pharmaceutical Ingredients (APIs), advanced intermediates and
enhanced drug delivery products for branded and generic
pharmaceuticals. Development and manufacturing capabilities include
enzymatic biotransformations, high potency APIs, high energy
chemical synthesis and controlled substances. For more
information, please visit www.cambrex.com
Contact:
Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155
Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Apr 2023 to Apr 2024